ELVN Form 144: Affiliates Report 9,086-Share Sale

ELVN affiliates reported proposed sales of Common Stock under Form 144, with broker-handled orders and a recent resale by a fund.

Rhea-AI Filing Summary

ELVN affiliates reported proposed sales of Common Stock under Form 144, with broker-handled orders and a recent resale by a fund. Examples include OrbiMed Genesis Master Fund selling 9,086 shares on 06/15/2026 and broker entries showing 24,846 shares (Jefferies LLC). Shares outstanding were 69,822,989 as of 06/22/2026.

The filing lists broker participants and an earlier issuer-related line dated 02/23/2023 showing 26,323 shares. The notice documents proposed and recent transactions; timing and proceeds mechanics follow the sale notices provided.

Insights

Equity Capital Markets Analyst

Form 144 filings show proposed/resale activity, including broker-handled orders and a recent fund sale.

The excerpt lists broker entries (Jefferies LLC and Morgan Stanley) with discrete share amounts and a reported sale by OrbiMed Genesis Master Fund of 9,086 shares on 06/15/2026. These items are transactional notices of proposed or completed dispositions rather than corporate financing events.

Investor impact depends on the scale relative to the company's 69,822,989 shares outstanding as of 06/22/2026. Subsequent filings or trade reports will show execution details.

Compliance / SEC Filings Specialist

Form 144 is a regulatory notice of proposed resale by affiliates/brokers, documenting method and quantities.

The excerpt records multiple entries including an issuer-related line dated 02/23/2023 and broker-handled quantities; it also records a past three‑month sale by an institutional holder. These entries satisfy notice requirements for resale under Rule 144 procedures.

Review of subsequent trade confirmations or broker reports is necessary to confirm actual market execution and proceeds.

Key Figures

OrbiMed sale: 9,086 shares OrbiMed proceeds listed: $409,051.72 Jefferies-listed quantity: 24,846 shares +3 more

6 metrics

OrbiMed sale 9,086 shares sale on <date>06/15/2026</date>

OrbiMed proceeds listed $409,051.72 amount tied to 9,086-share sale

Jefferies-listed quantity 24,846 shares broker entry associated with Jefferies LLC

Morgan Stanley-listed quantity 1,477 shares broker entry associated with Morgan Stanley & Co. LLC

Shares outstanding 69,822,989 as of <date>06/22/2026</date>

Issuer-related line (02/23/2023) 26,323 shares line dated <date>02/23/2023</date> labeled Merger / Issuer

Key Terms

Form 144, Merger, Selling broker, Past 3 months sale

4 terms

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Merger corporate

"Common Stock | 02/23/2023 | Merger | Issuer"

A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.

Selling broker market

"Jefferies LLC 520 Madison Ave New York NY 10022"

Past 3 months sale regulatory

"Securities Sold During The Past 3 Months | 06/15/2026 | 9086"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ELVN's Form 144 disclose about recent sales?

It discloses proposed and recent sales of Common Stock by affiliates and brokers. The excerpt shows a sale by OrbiMed Genesis Master Fund of 9,086 shares on 06/15/2026 and broker-listed entries including 24,846 shares.

How many ELVN shares were outstanding according to the filing?

The filing lists 69,822,989 shares outstanding as of 06/22/2026. This provides the baseline for assessing the relative size of the disclosed dispositions and broker entries.

Who are the brokers or intermediaries named in the Form 144?

The excerpt names brokers including Jefferies LLC and Morgan Stanley & Co. LLC with listed share quantities. These entries reflect broker-handled resale notices in the filing excerpt.

Does the filing state proceeds or settlement details for the sales?

The excerpt records share counts and dollar amounts for some rows, such as $409,051.72 tied to the 9,086-share sale, but it does not provide full settlement mechanics or buyer identities in the visible lines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 08:13 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001055951
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 Lookout Road Boulder COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	OrbiMed Genesis Master Fund, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Jefferies LLC 520 Madison Ave New York NY 10022	24846	1141922.16	69822989	06/22/2026	Nasdaq Stock Market
Common Stock	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	1477	67882.92	69822989	06/22/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/23/2023	Merger	Issuer			26323	02/23/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
OrbiMed Genesis Master Fund, L.P. 601 Lexington Ave 54th Floor New York NY 10022	Common Stock	06/15/2026	9086	409051.72

144: Remarks and Signature

Remarks	OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC.
Date of Notice	06/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Genesis Master Fund, L.P.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)